{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:39Z","timestamp":1789469139220,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07111-z","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:13:23Z","timestamp":1780751603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Splicing factor mutations clearance and outcomes in clonal myeloid neoplasms: a referral center experience"],"prefix":"10.1007","volume":"105","author":[{"given":"Manasawee","family":"Tanariyakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avani","family":"Yaganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalothorn","family":"Wannaphut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwal","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grerk","family":"Sutamtewagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-7093","authenticated-orcid":false,"given":"Kittika","family":"Poonsombudlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"5","key":"7111_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA et al (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374(5):422\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1507471","journal-title":"N Engl J Med"},{"issue":"19","key":"7111_CR2","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A et al (2024) Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19):1931\u20131936. https:\/\/doi.org\/10.1182\/blood.2023023096","journal-title":"Blood"},{"issue":"13","key":"7111_CR3","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","volume":"6","author":"NJ Short","year":"2022","unstructured":"Short NJ, Kantarjian H, Ravandi F et al (2022) High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006\u20134014. https:\/\/doi.org\/10.1182\/bloodadvances.2022007378","journal-title":"Blood Adv"},{"issue":"5","key":"7111_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002088","volume":"21","author":"B Wu","year":"2023","unstructured":"Wu B, Chen X, Pan X et al (2023) Single-cell transcriptome analyses reveal critical roles of RNA splicing during leukemia progression. PLoS Biol 21(5):e3002088. https:\/\/doi.org\/10.1371\/journal.pbio.3002088","journal-title":"PLoS Biol"},{"issue":"23","key":"7111_CR5","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1182\/bloodadvances.2020003235","volume":"5","author":"C Pavlovsky","year":"2021","unstructured":"Pavlovsky C, Abello Polo V, Pagnano K et al (2021) Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Adv 5(23):4855\u20134863. https:\/\/doi.org\/10.1182\/bloodadvances.2020003235","journal-title":"Blood Adv"},{"issue":"11","key":"7111_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2025031480","volume":"147","author":"J Cloos","year":"2026","unstructured":"Cloos J, Valk PJM, Thiede C et al (2026) 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD working party. Blood 147(11):1147\u20131167. https:\/\/doi.org\/10.1182\/blood.2025031480","journal-title":"Blood"},{"issue":"1","key":"7111_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita K, Wang F, Jahn K et al (2020) Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5327. https:\/\/doi.org\/10.1038\/s41467-020-19119-8","journal-title":"Nat Commun"},{"issue":"9","key":"7111_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.trecan.2023.05.004","volume":"9","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, Tanaka T (2023) Clonal evolution and hierarchy in myeloid malignancies. Trends Cancer 9(9):707\u2013715. https:\/\/doi.org\/10.1016\/j.trecan.2023.05.004","journal-title":"Trends Cancer"},{"issue":"12","key":"7111_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"7","key":"7111_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"issue":"7","key":"7111_CR11","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL et al (2022) Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid Jul 1(7):EVIDoa2200008. https:\/\/doi.org\/10.1056\/EVIDoa2200008","journal-title":"NEJM Evid Jul"},{"issue":"10","key":"7111_CR12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Galli A, Such E et al (2016) Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 128(10):1408\u201317. https:\/\/doi.org\/10.1182\/blood-2016-05-714030","journal-title":"Blood"},{"issue":"17","key":"7111_CR13","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/blood.2022018604","volume":"141","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP et al (2023) Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. Blood 141(17):2047\u20132061. https:\/\/doi.org\/10.1182\/blood.2022018604","journal-title":"Blood"},{"issue":"12","key":"7111_CR14","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1038\/s41375-022-01734-7","volume":"36","author":"S Huber","year":"2022","unstructured":"Huber S, Haferlach T, Meggendorfer M et al (2022) SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase. Leukemia 36(12):2927\u20132930. https:\/\/doi.org\/10.1038\/s41375-022-01734-7","journal-title":"Leukemia"},{"key":"7111_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061232","author":"Y Ochi","year":"2021","unstructured":"Ochi Y, Ogawa S (2021) Chromatin-spliceosome mutations in acute myeloid leukemia. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13061232","journal-title":"Cancers (Basel)"},{"issue":"8","key":"7111_CR16","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","volume":"5","author":"CA Lachowiez","year":"2021","unstructured":"Lachowiez CA, Loghavi S, Furudate K et al (2021) Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with Venetoclax. Blood Adv 5(8):2173\u20132183. https:\/\/doi.org\/10.1182\/bloodadvances.2020004173","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"7111_CR17","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1182\/blood-2025-3396","volume":"146","author":"Y Abu-Farsakh","year":"2025","unstructured":"Abu-Farsakh Y, Zabor E, Albliwi M et al (2025) Spliceosome mutations in AML: Prevalence, clinical features, and treatment outcomes in a contemporary cohort. Blood 146(Supplement 1):3396\u20133396. https:\/\/doi.org\/10.1182\/blood-2025-3396","journal-title":"Blood"},{"issue":"2","key":"7111_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ et al (2020) Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 382(2):140\u2013151. https:\/\/doi.org\/10.1056\/NEJMoa1908892","journal-title":"N Engl J Med"},{"issue":"19","key":"7111_CR19","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1002\/cncr.33745","volume":"127","author":"R Kanagal-Shamanna","year":"2021","unstructured":"Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K et al (2021) Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127(19):3552\u20133565. https:\/\/doi.org\/10.1002\/cncr.33745","journal-title":"Cancer"},{"issue":"12","key":"7111_CR20","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1038\/s41375-024-02374-9","volume":"38","author":"M Yacout","year":"2024","unstructured":"Yacout M, Katamesh B, Jabban Y et al (2024) Characterisation and prognostic impact of ZRSR2 mutations in myeloid neoplasms. Leukemia 38(12):2727\u20132730. https:\/\/doi.org\/10.1038\/s41375-024-02374-9","journal-title":"Leukemia"},{"issue":"8","key":"7111_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1182\/blood.2019004260","volume":"138","author":"S Chen","year":"2021","unstructured":"Chen S, Benbarche S, Abdel-Wahab O (2021) Splicing factor mutations in hematologic malignancies. Blood 138(8):599\u2013612. https:\/\/doi.org\/10.1182\/blood.2019004260","journal-title":"Blood"},{"issue":"11","key":"7111_CR22","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s00277-023-05442-9","volume":"102","author":"PJP Croucher","year":"2023","unstructured":"Croucher PJP, Ridinger M, Becker PS et al (2023) Spliceosome mutations are associated with clinical response in a phase 1b\/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Ann Hematol 102(11):3049\u20133059. https:\/\/doi.org\/10.1007\/s00277-023-05442-9","journal-title":"Ann Hematol"},{"key":"7111_CR23","doi-asserted-by":"publisher","unstructured":"Garcia-Manero G, Platzbecker U, Lim K-H et al (2024) Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer. Review. Frontiers in Hematology\u00a03. https:\/\/doi.org\/10.3389\/frhem.2024.1339870","DOI":"10.3389\/frhem.2024.1339870"},{"issue":"Supplement 1","key":"7111_CR24","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2024-195793","volume":"144","author":"AM Brunner","year":"2024","unstructured":"Brunner AM, Liu Y, Garcia JS et al (2024) Clinical activity and safety of the oral ATR inhibitor Ceralasertib (AZD6738) in patients with MDS or CMML after prior HMA therapy. Blood 144(Supplement 1):1833\u20131833. https:\/\/doi.org\/10.1182\/blood-2024-195793","journal-title":"Blood"},{"key":"7111_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241275376","volume":"15","author":"J Watts","year":"2024","unstructured":"Watts J, Minden MD, Bachiashvili K et al (2024) Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms. Therapeutic Advances in Hematology 15:20406207241275376. https:\/\/doi.org\/10.1177\/20406207241275376","journal-title":"Therapeutic Advances in Hematology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07111-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07111-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07111-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:46Z","timestamp":1789465366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07111-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7111"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07111-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have made substantial contributions to the data collection, data analysis, manuscript concept, production, and approve of this manuscript in its entirety.","order":1,"name":"Ethics","label":"Authorship","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"supplementary data related to this manuscript are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","label":"Data transparency","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors expect PD declare no competing interests related to the production of this manuscript. PD reports receiving consulting fees from AbbVie\/Genentech, Geron, Stemline Therapeutics, and PRIME Education, LLC, and honoraria from Aplastic Anemia and MDS International Foundation, Binayatara Foundation, and Iowa Cancer Society.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"367"}}